Statin-Associated Myopathy Risk

Introduction to Statin Myopathy

The American College of Cardiology states that all currently marketed statins have clinically equivalent rates of severe myopathy, with rates around 0.08-0.09%, except for cerivastatin which had higher rates 1, 2

The ACC/AHA/NHLBI guidelines conclude that there are no clinically important differences in the rate of fatal rhabdomyolysis among the five statins available (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin), with all showing rates of severe myopathy around 0.08-0.09% 1, 2
The American College of Cardiology guidelines explicitly state that clinicians should consider the rates of severe myopathy as equivalent among all approved statins 1, 2

When patients develop muscle symptoms on one statin, switching to pravastatin or fluvastatin is recommended due to fewer drug interactions and potentially better tolerability in clinical practice 3

Once-weekly rosuvastatin can be considered as an alternative dosing strategy to reduce myopathy risk while maintaining some LDL-C reduction 3
Lower doses of any statin should be used, as myopathy risk is dose-dependent 3

Advanced age (especially >80 years), female gender, small body frame, frailty, chronic renal insufficiency, multisystem disease, hypothyroidism, drug interactions with cytochrome P-450 inhibitors, and perioperative periods are key risk factors to address before attributing symptoms to the statin itself 3

The rate of life-threatening rhabdomyolysis remains extremely rare (less than 1 death per million prescriptions) across all statins 1, 2
The distinction between subjective muscle complaints and objective myopathy with CK elevation is critical, as many muscle symptoms occur at similar rates in placebo groups 2